Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rizatriptan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D known ✓ | P28221 | 5/20 | 1.00 |
| ▸ | HTR1B known ✓ | P28222 | 5/20 | 1.00 |
| ▸ | HTR1A | P08908 | 12/20 | 1.00 |
| ▸ | HTR2C | P28335 | 9/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | HTR5A | P47898 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rizatriptan SCHEMBL12802834 | 1.00 | HTR1A (1.00) | HTR1AHTR2CHTR1DHTR1BADRA2C | |
| Rizatriptan SCHEMBL29407208 | 1.00 | HTR1A (1.00) | HTR1AHTR2CHTR1DHTR1BADRA2C | |
| Rizatriptan SCHEMBL28815652 | 0.99 | HTR1A (0.98) | HTR1AHTR2CHTR1DHTR1BADRA2C | |
| Rizatriptan SCHEMBL28840728 | 0.94 | HTR1A (0.88) | HTR1AHTR2CHTR1DHTR1BADRA2C | |
| Rizatriptan SCHEMBL2231061 | 0.94 | HTR1A (0.88) | HTR1AHTR2CHTR1DHTR1BADRA2C | |
| Rizatriptan SCHEMBL8809846 | 0.93 | HTR1A (0.86) | HTR1AHTR2CHTR1DHTR1BADRA2C | |
| Rizatriptan SCHEMBL1650947 | 0.93 | HTR1A (0.86) | HTR1AHTR2CHTR1DHTR1BADRA2C | |
| Rizatriptan SCHEMBL8809854 | 0.93 | HTR1A (0.86) | HTR1AHTR2CHTR1DHTR1BADRA2C | |
| Rizatriptan SCHEMBL3462253 | 0.92 | HTR1A (0.85) | HTR1AHTR2CHTR1DHTR1BADRA2C | |
| Rizatriptan SCHEMBL2326617 | 0.91 | HTR1A (0.83) | HTR1AHTR2CHTR1DHTR1BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 16146 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075410-A | Dry powder composition for intranasal delivery | — | 2026-05-26 | — | — | CN | claimed |
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | APTARGROUP, INC. (US) | 2026-05-14 | — | — | US | claimed |
| EP-4740962-A1 | PHARMACEUTICAL COMPOSITION, FORMULATION CONTAINING PHARMACEUTICAL COMPOSITION, KIT CONTAINING PHARMACEUTICAL COMPOSITION, PREPARATION METHOD FOR PHARMACEUTICAL COMPOSITION, AND USE OF PHARMACEUTICAL COMPOSITION | Shanghai WD Pharmaceutical Co., Ltd (CN) | 2026-05-13 | — | — | EP | claimed |
| EP-4734974-A1 | CANNABINOID COMPOSITION FOR USE IN THE TREATMENT OF PAIN AND/OR INFLAMMATION | Mabewo Phytopharm AG (CH) | 2026-05-06 | — | — | EP | claimed |
| WO-2026090164-A1 | COMPOSITIONS COMPRISING ELISMETREP AND A SECOND THERAPEUTIC AGENT FOR TREATING OR PREVENTING MIGRAINE OR PAIN | KALLYOPE, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| US-12611413-B2 | Pharmaceutical compositions comprising meloxicam | AXSOME THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | claimed |
| US-20260077048-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | AXSOME THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | claimed |
| US-20260069603-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | AXSOME THERAPEUTICS INC (US) | 2026-03-12 | — | — | US | claimed |
| CN-121570440-A | High-water permeability and high-adhesion pressure-sensitive adhesive patch matrix and preparation method and application thereof | 沈阳药科大学 | 2026-02-27 | — | — | CN | claimed |
| WO-1998002186-A1 | INCLUSION COMPLEX CONTAINING INDOLE SELECTIVE SEROTONIN AGONIST | FARMARC NEDERLAND B.V. (NL) | 1998-01-22 | — | — | WO | claimed |
| EP-0497512-B1 | Imidazole, triazole and tetrazole derivatives | MERCK SHARP & DOHME (GB) | 1997-09-24 | — | — | EP | claimed |
| EP-0778275-A1 | Process for the preparation of imidazole, triazole and tetrazole derivatives and their use as selective 5-HT-1 receptor agonists | MERCK SHARP & DOHME LTD. (GB) | 1997-06-11 | — | — | EP | claimed |
| US-5602162-A | TREATMENT AND/OR PREVENTION OF MIGRAINE | MERCK, SHARP & DOHME LTD. (GB) | 1997-02-11 | — | — | US | claimed |
| US-5567824-A | CATALYZING THE CYCLIZATION IN PRESENCE OF A SOLVENT AND A PROTON ACCEPTOR | MERCK & CO., INC. (US) | 1996-10-22 | — | — | US | claimed |
| US-5527817-A | N,N-DIMETHYL-2-(5-(1,2,4-TRIAZOL-1-YLMETHYL)-1H-INDOL-3-YL) ETHYLAMINE; SELECTIVE AGONIST OF 5-HT1-LIKE RECEPTORS; USEFUL IN TREATMENT OF MIGRAINES | MERCK SHARP & DOHME LIMITED (GB) | 1996-06-18 | — | — | US | claimed |
| US-5298520-A | Triazole containing indole derivatives | MERCK SHARP & DOHME LIMITED (GB) | 1994-03-29 | — | — | US | claimed |
| WO-1993025547-A1 | THE SULPHATE SALT OF A SUBSTITUTED TRIAZOLE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN THERAPY | MERCK SHARP & DOHME LIMITED (GB) | 1993-12-23 | — | — | WO | claimed |
| EP-0573221-A1 | The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy | MERCK SHARP & DOHME LTD. (GB) | 1993-12-08 | — | — | EP | claimed |
| EP-0497512-A2 | Imidazole, triazole and tetrazole derivatives | MERCK SHARP & DOHME LTD. (GB) | 1992-08-05 | — | — | EP | claimed |